First Turn Management’s Cytokinetics CYTK Stock Holding History

First Turn Management's CYTK Position: Q2 2026 in Review

First Turn Management increased its Cytokinetics (CYTK) stake by 86% in Q2 2026, buying an estimated $17.5M and bringing the position to 527,412 shares worth $44.9M. The position accounts for 4.81% of the portfolio, ranked #8.

First Turn Management first reported a position in CYTK in Q4 2023 and has held it in 8 quarters since. The position peaked at $67.4M in Q4 2023. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

• First Turn Management held 527,412 shares of Cytokinetics worth $44.9M as of Q2 2026.
• First Turn Management bought 243,712 Cytokinetics shares in Q2 2026, an estimated $17.5M.
• Cytokinetics made up 4.81% of First Turn Management's portfolio in Q2 2026, its #8 holding.
• First Turn Management first reported a position in Cytokinetics in Q4 2023 and has held it in 8 quarters since.
• First Turn Management's Cytokinetics position peaked at $67.4M in Q4 2023.
• 483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on First Turn Management's 13F filing for Q2 2026, filed 14 Aug 2026.